This medicine is now known as satralizumab.
On 27 June 2016, orphan designation (EU/3/16/1680) was granted by the European Commission to Chugai Pharma Europe Ltd, UK, for humanised anti-IL-6 receptor monoclonal antibody (also known as SA237) for the treatment of neuromyelitis optica spectrum disorders.
The sponsorship was transferred to Chugai Pharma France, France, in January 2019.
The sponsorship was transferred to Roche Registration GmbH, Germany, in August 2019.
Humanised anti-IL-6 receptor monoclonal antibody (satralizumab)
|Disease / condition||
Treatment of neuromyelitis optica spectrum disorders
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.